netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund List

The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).

 Details...
08.02.04  Expand sub section  Other immunomodulating drugs
Axicabtagene ciloleucel
(Yescarta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
   
BCG bladder instillation

(OncoTICE)
View SPC online  Track Changes
Formulary
Red

Powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG.

 
   
Daclizumab (Zinbryta®)
View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

WITHDRAWN FROM MARKET

MHRA advice: Daclizumab (Zinbryta▼): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy (March 2018).

 
Link  EMA update on Daclizumab (Zinbryta)
Link  NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
   
Dimethyl fumarate (Tecfidera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
   
Fingolimod (Gilenya®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

MHRA/CHM advice: Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy (April 2017)

MHRA/CHM advice: Fingolimod—not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose and following treatment interruption (January 2013)

MHRA/CHM advice: Fingolimod: new contra-indications in relation to cardiac risk (December 2017)

MHRA/CHM advice: Fingolimod: updated advice about risk of cancers and serious infections (December 2017)

MHRA advice (Sep 2019): Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception

 
Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
   
Glatiramer acetate (Copaxone®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with DH drug treatments for multiple sclerosis: risk-sharing scheme (HSC 2002/004) briefing note November 2006

Restriction: In line with NICE Guidance only

 
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon Alfa 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
 
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
   
Interferon Beta 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with DH drug treatments for multiple sclerosis: risk-sharing scheme (HSC 2002/004) briefing note November 2006

Restriction: In line with NICE Guidance only

 
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Lenalidomide (Revlimid®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.

 
Link  NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
   
Lenalidomide plus Dexamethasone
(Revlimide®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib
Link  NICE TA587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma
   
Mifamurtide (Mepact®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

 
Link  NICE TA235: Mifamurtide for the treatment of osteosarcoma
   
Natalizumab (Tysabri®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
   
Peginterferon Alfa (Pegasys®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Link  NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Link  NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Link  NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Link  NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
   
Pomalidomide (Imnovid®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.

MHRA/CHM advice (May 2016): Risk of hepatitis B reactivation

 
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
   
Rucaparib (Rubraca®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE guidance only

 
Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
   
Teriflunomide (Aubagio®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
   
Thalidomide (Celgene®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a complete Prescription Authorisation Form.

 
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary